Inhibition of SMYD2 suppressed the progression of ccRCC in vivo and in vitro by dysregulating miR-125b, which acted as a tumor promoting factor in ccRCC. This evidence concerns the gene SMYD2 and nonpapillary renal cell carcinoma.